Please use this identifier to cite or link to this item:
http://hdl.handle.net/1893/28322
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | McIntosh, Bryan | en_UK |
dc.contributor.author | Fascia, Michael | en_UK |
dc.date.accessioned | 2018-11-29T01:03:20Z | - |
dc.date.available | 2018-11-29T01:03:20Z | - |
dc.date.issued | 2014-12-31 | en_UK |
dc.identifier.uri | http://hdl.handle.net/1893/28322 | - |
dc.description.abstract | T-lymphocytes (T-cell) therapy offers a treatment for cancers. Developing this technology in the future provides the opportunity to revolutionise treatment and to make cancer a chronic condition. T-cells in themselves are a type of lymphocytes (itself a type of white blood cell) that play a central role in cell mediated immunity. They can be distinguished from other lymphocytes, such as B-cells and natural killer cells (NK cells), by the presence of a T-cell receptor (TCR) on the cell surface. T-cells have the capacity to destroy diseased cells, but tumours present a considerable challenge that reduces their impact. As cancer cells are frequently ‘invisible’ to the immune system, and they create an environment that suppresses T-cell activity., genetic engineering of T-cells can be used therapeutically to overcome these challenges. T-cells can be taken from the blood of cancer patients and then modified to recognise and destroy cancer-specific antigens. | en_UK |
dc.language.iso | en | en_UK |
dc.publisher | Mark Allen Healthcare | en_UK |
dc.relation | McIntosh B & Fascia M (2014) The Highest Mountain: T-Cell Technology. British Journal of Healthcare Management, 20 (6), pp. 281-285. https://doi.org/10.12968/bjhc.2014.20.6.281 | en_UK |
dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in British Journal of Healthcare Management, copyright © MA Healthcare, after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.12968/bjhc.2014.20.6.281 | en_UK |
dc.subject | Cancer | en_UK |
dc.subject | Leukaemia | en_UK |
dc.subject | T-cells | en_UK |
dc.subject | Immunosuppression | en_UK |
dc.subject | T-cell receptor | en_UK |
dc.subject | TCR | en_UK |
dc.title | The Highest Mountain: T-Cell Technology | en_UK |
dc.type | Journal Article | en_UK |
dc.identifier.doi | 10.12968/bjhc.2014.20.6.281 | en_UK |
dc.citation.jtitle | British Journal of Healthcare Management | en_UK |
dc.citation.issn | 1759-7382 | en_UK |
dc.citation.issn | 1358-0574 | en_UK |
dc.citation.volume | 20 | en_UK |
dc.citation.issue | 6 | en_UK |
dc.citation.spage | 281 | en_UK |
dc.citation.epage | 285 | en_UK |
dc.citation.publicationstatus | Published | en_UK |
dc.citation.peerreviewed | Refereed | en_UK |
dc.type.status | AM - Accepted Manuscript | en_UK |
dc.citation.date | 02/06/2014 | en_UK |
dc.contributor.affiliation | University of Bradford | en_UK |
dc.contributor.affiliation | University of Edinburgh | en_UK |
dc.identifier.scopusid | 2-s2.0-84907914352 | en_UK |
dc.identifier.wtid | 1039766 | en_UK |
dc.contributor.orcid | 0000-0002-4872-170X | en_UK |
dcterms.dateAccepted | 2014-06-02 | en_UK |
dc.date.filedepositdate | 2018-11-22 | en_UK |
rioxxterms.apc | not required | en_UK |
rioxxterms.type | Journal Article/Review | en_UK |
rioxxterms.version | AM | en_UK |
local.rioxx.author | McIntosh, Bryan|0000-0002-4872-170X | en_UK |
local.rioxx.author | Fascia, Michael| | en_UK |
local.rioxx.project | Internal Project|University of Stirling|https://isni.org/isni/0000000122484331 | en_UK |
local.rioxx.freetoreaddate | 2018-11-22 | en_UK |
local.rioxx.licence | http://www.rioxx.net/licenses/all-rights-reserved|2018-11-22| | en_UK |
local.rioxx.filename | 76944737.pdf | en_UK |
local.rioxx.filecount | 1 | en_UK |
local.rioxx.source | 1759-7382 | en_UK |
Appears in Collections: | Faculty of Health Sciences and Sport Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
76944737.pdf | Fulltext - Accepted Version | 245.29 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/
If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.